Australian Retatrutide Approval Tracker
A status board for retatrutide regulatory milestones in Australia, including what is known and what isn't public yet.
Direct answer
The tracker is intentionally conservative: no TGA approval today, no Australian prescription product today, and no official PBS price today.
Current read
You are waiting for approval first.
A GP prescription path needs a TGA-approved product. The tracker stays red until an official Australian approval exists.
01
TRIUMPH-1 topline data
Reported
Lilly reported topline Phase 3 TRIUMPH-1 results on 21 May 2026.
02
Regulatory filing
Not confirmed for Australia
A filing is the next public milestone to watch. Without it, there is no Australian approval clock.
03
TGA approval
Not approved
No TGA-approved Australian retatrutide medicine is listed by this site as of the latest update.
04
Pharmacy product
Not available
Without approval and launch, there is no Australian pharmacy retatrutide product today.
05
PBS decision
No listing
PBS status would come after approval, launch, supply, and reimbursement decisions.
Last updated 26 May 2026. This is a public-status tracker, not medical advice and not an official TGA, Lilly, pharmacy, or PBS record.
Tool output is for evidence review only. It's not medical advice, treatment advice, dosing guidance, or a personal outcome prediction.
Research peptides are not approved by the TGA for human use. Supplier links are for checking visible batch and payment details, not medical advice.
Is retatrutide TGA approved today?+
No. This tracker treats retatrutide as investigational unless an official Australian approval record becomes public.
What changes first?+
The usual sequence is trial data, regulatory filing, regulator review, approval decision, launch, then pricing or PBS decisions.
Can this page give a launch date?+
No. It can show the current public status and the next milestone, but any exact Australian launch date before approval is a guess.
Other tools
Useful checks beat loud claims.